Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Crosses Above 200 Day Moving Average – Here’s What Happened

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $5.54 and traded as high as $6.75. Cumberland Pharmaceuticals shares last traded at $6.12, with a volume of 741,873 shares.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Cumberland Pharmaceuticals has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Down 11.3%

The business has a 50-day moving average price of $6.65 and a two-hundred day moving average price of $5.56. The company has a market capitalization of $88.08 million, a price-to-earnings ratio of 1.31 and a beta of 0.16.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CPIX. Diversified Trust Co bought a new stake in shares of Cumberland Pharmaceuticals during the third quarter worth about $5,481,000. Lantern Wealth Advisors LLC acquired a new position in Cumberland Pharmaceuticals during the 3rd quarter valued at about $106,000. BlackRock Inc. acquired a new position in Cumberland Pharmaceuticals during the 2nd quarter valued at about $412,000. Bank of New York Mellon Corp purchased a new stake in shares of Cumberland Pharmaceuticals in the second quarter worth approximately $379,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Cumberland Pharmaceuticals in the first quarter worth approximately $66,000. 15.51% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions. Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation.